Skip to content

Stoke Therapeutics

US · STOK #2942 by market cap Listed 2019
26.81 -0.12 -0.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
    Market Newswire · 2026/5/8
  • Rating change
    CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/3/20
  • Rating change
    TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/10/13
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)
    TipRanks · 2026/8/4
  • Rating change
    A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60
    Market Newswire · 2026/8/5
  • Rating change
    J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/8/21
  • CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/11/3
  • Rating change
    Goldman Sachs Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $44
    Market Newswire · 2026/10/6
  • Rating change
    Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/8/4
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Genelux Corp. (GNLX) and Celldex (CLDX)
    TipRanks · 2026/5/9
  • Rating change
    Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/5/8
  • Goldman Sachs Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Cuts Target Price to $43
    Market Newswire · 2026/10/30
  • Rating change
    Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/7/9
  • Rating change
    Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44
    Market Newswire · 2026/7/14
  • BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/11/2
  • Rating change
    A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60
    Market Newswire · 2026/5/9
  • Rating change
    Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $38
    Market Newswire · 2026/3/18
  • Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q3 Revenue $11.3M, Vs. FactSet Est of $8.2M
    MT Newswires · 2026/10/30
  • Rating change
    Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/3/17
  • H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/11/3
  • Rating change
    H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/4/22
  • BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/10/12
  • Rating change
    CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/8/13
  • Rating change
    Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/3/17
  • Rating change
    Wolfe Research Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/2/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Stoke Therapeutics discussion 0 comments

Add a comment